Combination Therapy of Raloxifene and Alendronate for Treatment of Osteoporosis in Elderly Women
0
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objectives: To evaluate and compare the efficacy and safety of the combination of raloxifene and alendronate with those ofmonotherapies in elderly women with osteoporosis. Methods: Sixty-two postmenopausal women (mean age 63.5 ± 0.5 years) attending gynecologic osteoporosis clinics withestablished osteoporosis were randomly allocated to one of four treatment groups and monitored for 3 years. All patients enrolledin this study, including those in the control group (n = 14), received 1.0 g elemental calcium and 400 units of vitamin D per day. The raloxifene group (n = 16) received raloxifene 60 mg (Evista®) per day; alendronate group (n = 17) received low-dose (5 mg)alendronate with calcitriol 0.5 μg (Maxmarvil®) per day; and the combination therapy group (n = 15) received both raloxifene 60mg and low-dose (5 mg) alendronate with calcitriol 0.5 μg. Bone mineral density (BMD) was measured in the lumbar spine and hipbefore and after 3 years of treatment. Results: In patients who received the combined therapy, BMD increased in the lumbar spine and the hip by 7.2% (P < 0.001)and 4.8% (P < 0.001) at 3 years. For patients in the alendronate group, the increases were 6.7% (P < 0.001) and 3.1% (P < 0.01)respectively, for the raloxifene group, the increases were 4.36% (P < 0.001) and 1.9% (P < 0.05) in the vertebrae and femora,respectively; however, the BMD of patients in the control group decreased by 1.81% (P < 0.05) and 1.6% (P < 0.05), respectively,after 3 years. Patients who received the combination therapy had significantly higher BMD in both the vertebrae femora (P < 0.01)in comparison to that in those treated with raloxifene or alendronate individually. Conclusions: This 3-year randomized study showed the improved effects of alendronate and raloxifene combination on spine andhip BMD in elderly postmenopausal women with established osteoporosis. (J Menopausal Med 2017;23:56-62)
Abstract
Objectives: To evaluate and compare the efficacy and safety of the combination of raloxifene and alendronate with those ofmonotherapies in elderly women with osteoporosis. Methods: Sixty-two postmenopausal women (mean age 63.5 ± 0.5 years) attending gynecologic osteoporosis clinics withestablished osteoporosis were randomly allocated to one of four treatment groups and monitored for 3 years. All patients enrolledin this study, including those in the control group (n = 14), received 1.0 g elemental calcium and 400 units of vitamin D per day. The raloxifene group (n = 16) received raloxifene 60 mg (Evista®) per day; alendronate group (n = 17) received low-dose (5 mg)alendronate with calcitriol 0.5 μg (Maxmarvil®) per day; and the combination therapy group (n = 15) received both raloxifene 60mg and low-dose (5 mg) alendronate with calcitriol 0.5 μg. Bone mineral density (BMD) was measured in the lumbar spine and hipbefore and after 3 years of treatment. Results: In patients who received the combined therapy, BMD increased in the lumbar spine and the hip by 7.2% (P < 0.001)and 4.8% (P < 0.001) at 3 years. For patients in the alendronate group, the increases were 6.7% (P < 0.001) and 3.1% (P < 0.01)respectively, for the raloxifene group, the increases were 4.36% (P < 0.001) and 1.9% (P < 0.05) in the vertebrae and femora,respectively; however, the BMD of patients in the control group decreased by 1.81% (P < 0.05) and 1.6% (P < 0.05), respectively,after 3 years. Patients who received the combination therapy had significantly higher BMD in both the vertebrae femora (P < 0.01)in comparison to that in those treated with raloxifene or alendronate individually. Conclusions: This 3-year randomized study showed the improved effects of alendronate and raloxifene combination on spine andhip BMD in elderly postmenopausal women with established osteoporosis. (J Menopausal Med 2017;23:56-62)
참고문헌 (27)
- Cummings SR, "Epidemiology and outcomes of osteoporotic fractures", Lancet, 359, pp.1761~1767 (2002)
- Anonymous, "NIH consensus declares osteoporosis a major public health issue", Osteoporos Rep, 16, pp.1~ (2000)
- Jeong EH, "The effects of three-year hormone therapy, raloxifene and alendronate on bone miner al density in postmenopausal women", J Korean Soc Menopause, 15, pp.41~47 (2009)
- Rossouw JE, "Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results From the Women's Health Initiative randomized controlled trial", JAMA, 288, pp.321~333 (2000)
- Faulkner KG, "Bone matters: are density increases necessary to reduce fracture risk?", J Bone Miner Res, 15, pp.183~187 (2000)
- Silva BC, "Fracture Risk Prediction by Non-BMD DXA Measures: the 2015 ISCD Official Positions Part 2:Trabecular Bone Score", J Clin Densitom, 18, pp.309~330 (2015)
- Wasnich RD, "Antifracture efficacy of antiresorptive agents are related to changes in bone density", J Clin Endocrinol Metab, 85, pp.231~236 (2000)
- Hochberg MC, "Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents", J Clin Endocrinol Metab, 87, pp.1586~1592 (2002)
- Cummings SR, "Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs", Am J Med, 112, pp.281~289 (2002)
- Delmas PD, "Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis:four-year results from a randomized clinical trial", J Clin Endocrinol Metab, 87, pp.3609~3617 (2002)
- Bone HG, "Alendronate and estrogen effects in postmenopausal women with low bone mineral density", J Clin Endocrinol Metab, 85, pp.720~726 (2000)
- Fleisch H, "Bisphosphonates: mechanisms of action", Endocr Rev, 19, pp.80~100 (1998)
- 정수호, "폐경여성에서 호르몬 치료에 따른 골밀도 변화의 상호관계", 대한폐경학회지, 19(2), pp.101~105 (2013), 대한폐경학회
- Mitlak BH, "Selective estrogen receptor modulators: a look ahead", Drugs, 57, pp.653~663 (1999)
- Ettinger B, "Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators", JAMA, 282, pp.637~645 (1999)
- Hlaing TT, "Biochemical markers of bone turnover - uses and limitations", Ann Clin Biochem, 15, pp.189~202 (2014)
- Walsh BW, "Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women", JAMA, 279, pp.1445~1451 (1998)
- Walsh BW, "The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial", J Clin Endocrinol Metab, 85, pp.214~218 (2000)
- Goldstein SR, "A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium", Obstet Gynecol, 95, pp.95~103 (2000)
- Young Hwa Cho, "Raloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist for Severe Endometriosis: Effects on Bone Mineral Density", 대한폐경학회지, 22(3), pp.174~179 (2016), 대한폐경학회
- Freedman M, "Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo", J Natl Cancer Inst, 93, pp.51~56 (2001)
- Wimalawansa SJ, "A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis", Am J Med, 104, pp.219~226 (1998)
- Lindsay R, "Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial", J Clin Endocrinol Metab, 84, pp.3076~3081 (1999)
- Harris ST, "Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women", J Clin Endocrinol Metab, 86, pp.1890~1897 (2001)
- Greendale GA, "How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen", Progestin Interventions Trial, 2000, pp.160, 3065~3071
- Hee-Jeong Choi, "New Antiresorptive Therapies for Postmenopausal Osteoporosis", 대한폐경학회지, 21(1), pp.1~11 (2015), 대한폐경학회
- Greenspan SL, "Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebocontrolled, randomized clinical trial", J Clin Endocrinol Metab, 90, pp.2762~2767 (2005)